Provided by Tiger Fintech (Singapore) Pte. Ltd.

Biocryst Pharmaceuticals

8.86
+0.41504.92%
Volume:3.83M
Turnover:33.19M
Market Cap:1.85B
PE:-20.59
High:8.89
Open:8.34
Low:8.28
Close:8.44
Loading ...

BioCryst price target raised to $12 from $10 at Evercore ISI

TIPRANKS
·
13 Jan

Exploring High Growth Tech Stocks In January 2025

Simply Wall St.
·
11 Jan

BioCryst Pharmaceuticals Preliminary Q4 Revenue Rises

MT Newswires Live
·
10 Jan

BioCryst Pharmaceuticals up 6.5% Premarket After Co Forecasts $540-$560 Mln Total Revenue in 2025

THOMSON REUTERS
·
10 Jan

BioCryst Pharmaceuticals Q4 Product Sales USD 123.5 Million

THOMSON REUTERS
·
10 Jan

BioCryst Pharmaceuticals: Expects to Approach Quarterly EPS Profitability/Positive Cash Flow in 2H 2025

THOMSON REUTERS
·
10 Jan

BioCryst Pharmaceuticals: Orladeyo Net REV Expected to Be Between $515-$535 Mln in 2025

THOMSON REUTERS
·
10 Jan

BioCryst Pharmaceuticals: New Drug Application Planned in 2025 for Orladeyo Granules in Children up to Age 12

THOMSON REUTERS
·
10 Jan

BioCryst Pharmaceuticals: Total Revenue Expected to Be Between $540-$560 Mln in 2025

THOMSON REUTERS
·
10 Jan

BioCryst Announces Preliminary Full Year 2024 Orladeyo® (Berotralstat) Net Revenue of $437 Million (+34 Percent Y-O-Y)

THOMSON REUTERS
·
10 Jan

BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)

GlobeNewswire
·
10 Jan

BioCryst (BCRX) Receives a Buy from RBC Capital

TIPRANKS
·
10 Jan

BRIEF-Biocryst Pharmaceuticals Increases Wholesale Acquisition Cost For Orladeyo To $44,484.33 Per 28-Day Pack

Reuters
·
08 Jan

BioCryst Pharmaceuticals Inc - Increases Wholesale Acquisition Cost for Orladeyo to $44,484.33 per 28-Day Pack

THOMSON REUTERS
·
08 Jan

BioCryst reports inducement grants under Nasdaq listing rule

TIPRANKS
·
06 Jan

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
06 Jan

The 4.5% return this week takes BioCryst Pharmaceuticals' (NASDAQ:BCRX) shareholders five-year gains to 127%

Simply Wall St.
·
27 Dec 2024

KalVista Pharmaceuticals' Sebetralstat Poised to Disrupt Acute HAE Market With Oral Advantage, BofA Says

MT Newswires Live
·
18 Dec 2024

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
05 Dec 2024

RBC Capital Reaffirms Their Buy Rating on BioCryst (BCRX)

TIPRANKS
·
28 Nov 2024